Denis Wade - Biotron Independent Non-Executive Director
| BITRF Stock | USD 0.06 0.00 0.00% |
Director
Dr. Denis Newell Wade was Independent NonExecutive Director of Biotron Ltd since April 30, 2010. Dr. Wade was involved for over 40 years with the development of research based pharmaceuticals and medical devices in both industry and academia. He was a director of several private and public companies in the healthcare sector, including Heartware Limited and subsequently Heartware International Inc., since December 2004. He was a director and chairman of Gene Shears Pty Limited and, from 1987 until his retirement in 2002, was managing director and chairman of Johnson Johnson Research Pty Ltd, a research and development company of Johnson Johnson Inc. He was also a member of the JJ Corporationrationrate Office of Science and Technology. Prior to that, Dr. Wade was the Foundation Professor of Clinical Pharmacology at the University of New South Wales and served as a member of a number of state and federal bodies related to the drug industry, including the P3 Committee. He is a former chairman of the Australian Academy National Committee for Pharmacology, the Australasian Society for Clinical and Experimental Pharmacology and Toxicology and a former chairman of the Clinical Pharmacology Section of the International Union of Pharmacology since 2010.
| Age | 76 |
| Tenure | 14 years |
| Professional Marks | Ph.D |
| Phone | 61 2 9300 3344 |
| Web | https://www.biotron.com.au |
Biotron Management Efficiency
The company has return on total asset (ROA) of (0.5574) % which means that it has lost $0.5574 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.1224) %, meaning that it generated substantial loss on money invested by shareholders. Biotron's management efficiency ratios could be used to measure how well Biotron manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Oupa Shongwe | Barloworld Ltd ADR | 54 | |
| Frances Edozien | Barloworld Ltd ADR | 51 | |
| Donald Wilson | Barloworld Ltd ADR | 59 | |
| Babalwa Ngonyama | Barloworld Ltd ADR | 40 | |
| Neo Dongwana | Barloworld Ltd ADR | 44 | |
| Alexander Hamilton | Barloworld Ltd ADR | 68 | |
| Ngozichukwuka Edozien | Barloworld Ltd ADR | 48 | |
| Alexander Landia | Barloworld Ltd ADR | 50 | |
| Steven Pfeiffer | Barloworld Ltd ADR | 63 | |
| Nomavuso Mnxasana | Barloworld Ltd ADR | 60 | |
| Hester Hickey | Barloworld Ltd ADR | 62 | |
| Peter Schmid | Barloworld Ltd ADR | 53 | |
| Sango Ntsaluba | Barloworld Ltd ADR | 56 | |
| Gavin Knight | Barloworld Ltd ADR | N/A | |
| Dominic Sewela | Barloworld Ltd ADR | 51 | |
| Sibongile Mkhabela | Barloworld Ltd ADR | 60 | |
| Michael LynchBell | Barloworld Ltd ADR | 64 | |
Management Performance
| Return On Equity | -1.12 | |||
| Return On Asset | -0.56 |
Biotron Limited Leadership Team
Elected by the shareholders, the Biotron's board of directors comprises two types of representatives: Biotron inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biotron. The board's role is to monitor Biotron's management team and ensure that shareholders' interests are well served. Biotron's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biotron's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Thomas, Independent Non-Executive Director | ||
| BSc GCertAppFin, MD Director | ||
| Peter Nightingale, Company Secretary | ||
| Michael Hoy, Independent Non-Executive Chairman of the Board | ||
| Michelle Miller, CEO, Managing Director, Executive Director | ||
| Stephen Locarnini, Director | ||
| CA BEcon, Company Sec | ||
| Denis Wade, Independent Non-Executive Director | ||
| Stephen MD, Chief Officer | ||
| Susan Pond, Independent Non-Executive Director |
Biotron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Biotron a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.12 | |||
| Return On Asset | -0.56 | |||
| Profit Margin | (1.78) % | |||
| Operating Margin | (1.78) % | |||
| Current Valuation | 15.31 M | |||
| Shares Outstanding | 901.94 M | |||
| Shares Owned By Insiders | 14.13 % | |||
| Price To Earning | (3.04) X | |||
| Price To Book | 23.61 X | |||
| Price To Sales | 11.17 X |
Pair Trading with Biotron
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biotron position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biotron will appreciate offsetting losses from the drop in the long position's value.Moving against Biotron Pink Sheet
| 0.62 | HD | Home Depot Financial Report 21st of May 2024 | PairCorr |
| 0.6 | PG | Procter Gamble Financial Report 26th of July 2024 | PairCorr |
| 0.55 | NVO | Novo Nordisk AS Financial Report 2nd of May 2024 | PairCorr |
| 0.55 | NONOF | Novo Nordisk AS | PairCorr |
| 0.47 | JPM | JPMorgan Chase Financial Report 12th of July 2024 | PairCorr |
The ability to find closely correlated positions to Biotron could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biotron when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biotron - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biotron Limited to buy it.
The correlation of Biotron is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biotron moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biotron Limited moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biotron can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biotron Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Biotron Pink Sheet analysis
When running Biotron's price analysis, check to measure Biotron's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotron is operating at the current time. Most of Biotron's value examination focuses on studying past and present price action to predict the probability of Biotron's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotron's price. Additionally, you may evaluate how the addition of Biotron to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |